Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Journal of Neurology

- PMLiVE

Researchers suggest erectile dysfunction drugs could reduce risk of Alzheimer’s

The study found that men prescribed PDE5Is were 18% less likely to develop the disease

Biogen Idec building

Biogen to discontinue Alzheimer’s drug Aduhelm in favour of Eisai-partnered Leqembi

The post-marketing confirmatory study of the intravenous treatment will now be terminated

- PMLiVE

Researchers identify five rare cases of Alzheimer’s from historic medical treatments

The study found that c-hGH treatment transmitted the amyloid-beta protein, a hallmark of AD

- PMLiVE

UK government announces nearly £50m to expand dementia research sites

The funding will be used to enable more people to take part in clinical trials for dementia

- PMLiVE

Study shows blood test could be as accurate as lumbar punctures for detecting Alzheimer’s

ALZpath successfully detected levels of a form of the hallmark tau protein in the blood

- PMLiVE

Study suggests hearing aids could prevent onset and progression of dementia

People with severe hearing loss had an increased risk of up to 20% of developing dementia

- PMLiVE

Nanoparticle-delivered RNA could offer potential therapy for neuroinflammation

The study demonstrated a new way to deliver RNA to the brain's immune cells

- PMLiVE

Study identifies new amyloid-forming protein linked to early-onset dementia

The TAF15 protein is a new potential therapeutic for frontotemporal dementia

- PMLiVE

New report identifies key issues with NICE’s methods for evaluating Alzheimer’s drugs

Several disease-modifying treatments for use in Alzheimer's disease are at varying stages of development and regulatory approval

- PMLiVE

New £5m project launched to bring Alzheimer’s blood tests to the NHS

Blood tests for the condition could become available on the NHS within five years

- PMLiVE

Alzheimer’s Research UK survey highlights dementia knowledge gaps

The UK poll revealed that only 60% of adults know that dementia is a cause of death

Biogen Idec building

Biogen/Eisai’s Alzheimer’s disease drug shows promise as subcutaneous formulation

Eisai said it aims to apply for US approval of SC Leqembi by the end of March 2024

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links